Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-29 01:37:45 - browse：83138

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： J&J lung cancer data amount to new salvo against AstraZeneca

focus

hotspot

focus

WSS

Truvian presents data for its desktop blood

Why patients can’t get everything they want on drug pricing

Health tech investors get more selective as pandemic boom fades

The problems with dementia villages

Is there really a nursing shortage in the U.S.?

Merck, Daiichi strike cancer drug pact worth up to $22 billion

hotspot

Wikipedia

focus

Walensky prepares to leave CDC — and Congress — behind

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Medical leaders decry Supreme Court decision on affirmative action

Senate panel puts off hardest PBM reforms for another day

Medical records are filled with copy

Study on Amgen’s bispecific immunotherapy produces positive data

In age of alternative facts, a scholarly course on calling out crap

What it's like to live with paralysis for one psychologist

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Summit: How researchers deal with rejection

hotspot

What causes rare myocarditis in young men after Covid vaccines?

STAT Readout: Friday, Oct. 20 biotech updates

Democrats decry new health bill for going easy on private equity

Why a market frenzy over new weight loss drugs defies logic

Why a market frenzy over new weight loss drugs defies logic

Questions loom on AstraZeneca cancer drug as safety concerns ebb

focus

hotspot

focus

hotspot